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Abstract A proportion of the microtubule-associated protein, 
tau, is in an elevated state of phosphorylation in foetal and adult 
brain whereas all of the tau in paired helical filaments, which are 
characteristic of Alzheimer's disease is hyperphosphorylated; it 
is important therefore to elucidate the mechanisms that regulate 
tau phosphorylation. Here we describe results that show that 
although MAP kinase can hyperphosphorylate an in vitro, acti- 
vation of MAP kinase in transformed fibroblasts does not result 
in hyperphosphorylation of transfected tau, whereas glycogen 
synthase kinase-3~ (GSK-3~) when co-transfected with tan does 
result in tau hyperphosphorylation. The findings imply that GSK- 
3~ may be a stronger candidate than MAP kinase for inducing 
tau hyperphosphorylation i vivo. 
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1. Introduction 
Tau is a microtubule-associated protein that is expressed 
principally in neurones. Adult brain tau comprises six isoforms 
generated by alternative splicing of a single gene transcript. The 
isoforms differ by either having three or four imperfect homol- 
ogous repeat domains of 31 amino acids in the C-terminal half 
of the molecule, in addition both three and four repeat forms 
can each have zero, one or two non-homologous 29amino acid 
inserts towards the N-terminus [1]. Only the smallest isoform 
(i.e. three repeats and zero inserts) is expressed in foetal brain 
[21. 
Tau is most likely the principal structural component of the 
paired helical filaments (PHF) that are one of the characteristic 
neuropathological hallmarks of Alzheimer's disease [1]. The 
phosphorylation state oftau in PHF has been shown to be one 
of the properties that distinguish PHF-tau from normal tau 
since compared to tau isolated from normal adult brain, PHF- 
tau is hyperphosphorylated. However, if tau is isolated rapidly 
from adult brain, about 25% of the tau is in a similar hyper- 
phosphorylated state to PHF-tau and a significant proportion 
of foetal tau is also hyperphosphorylated [2-8]. Some of the 
phosphorylated sites in PHF-tau and in the hyper- 
phosphorylated fraction of adult and foetal tau have been iden- 
tified by protein sequencing and by mapping of epitopes for a 
panel of monoclonal antibodies that discriminate PHF-tau 
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from the non-hyperphosphorylated fraction of adult brain tau. 
These monoclonal antibodies differentiate au phosphorylation 
states by virtue of their dependency for binding to tau upon the 
presence or absence of phosphate on specific serine residues 
[9-14]. Most of the sites identified to date are serine residues 
immediately followed in the sequence of tau by a proline and 
hence, are likely to be phosphorylated by proline directed ki- 
nases. Indeed, several members of the proline-directed kinase 
family of protein kinases have been found to phosphorylate 
recombinant tau at these sites in vitro and generate the corre- 
sponding PHF-tau epitopes. The candidate proline-directed ki-
nases for generating hyperphosphorylated tau are certain mem- 
bers of the MAP kinase family (eg. p44 MAPK and p42 MAPK ), 
cdk5, and glycogen synthase kinases-3c~ and -3fl (GSK-3~, 
GSK-3fl) I11,15-18 I. 
The functions of tau include stabilisation of microtubules 
since treatment of primary cultures of neurones with antisense 
oligonucleotides to tau results in neurite retraction [19,20]. 
Phosphorylation f tau may be a regulatory mechanism for this 
function since increased levels of phosphorylation reduce or 
abolish (eg. PHF-tau) the ability oftau to bind to microtubules 
[9,21-25]. It is therefore of some interest o elucidate the regu- 
latory mechanisms for tau phosphorylation since they may be 
important in neurite outgrowth in the developing nervous ys- 
tem and may be aberrant in Alzheimer's disease. The next step, 
however, is to identify which of the candidate kinases are capa- 
ble of phosphorylating tau in living cells. 
We have previously reported that of the several MAP kinases 
and GSK-3c~ and GSK-3fl that can generate hyper- 
phosphorylated tau in vitro, only GSK-3a and GSK-3fl but not 
p44 MAPK nor p42 MAPK phosphorylate tau in COS cells tran- 
siently transfected with tau and kinase cDNAs [13]. In this 
earlier study, the activation of MAP kinase was only transient 
following treatment of transfected cells with TPA, whereas it 
might be that more prolonged MAP kinase activation would 
result in tau hyperphosphorylation. We now report that in 
mouse Swiss 3T3 cells transformed with the oncogene v-raft 
which results in constitutive activation of MAP kinase [26-28], 
the activated MAP kinase still did not result in the generation 
of PHF-tau-like hyperphosphorylation although when the 
MAP kinase activity was further elevated by co-transfection 
with a p44 MAPK cDNA and treatment of the cells with phorbol 
ester, the phosphorylation state of transfected tau was different 
from tau in non-transformed 3T3 cells. However, co-transfec- 
tion of the 3T3 cells with tau and GSK-3fl did induce hyper- 
phosphorylation f tau. 
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2. Materials and methods 
2.1. Cell culture and transfection 
Swiss 3T3 cells and v-raf-transformed Swiss 3T3 cells were routinely 
cultured in DMEM containing 10% (v/v) foetal bovine serum supple- 
mented with 2 mM glutamine and 100 U/ml penicillin and 100/zg/ml 
streptomycin, cDNAs encoding rat p44 MApK, human GSK-3fl and 
human tau with one N-terminal insert and four repeats (1N4R) were 
ligated into EcoRIIHindIII sites of the expression vector pGW1-CMV 
[29]. For transfection, cells were harvested by trypsinisation and resus- 
pended in Optimem medium (Life Technologies, Strathclyde, UK). 15 
pg of each plasmid DNA was introduced by electroporation using a 
BioRad electroporator perating at 0.22 kV, 960/zF in a 0.4 cm path 
length electroporation chamber containing 10 7 cells in 0.4 ml. Follow- 
ing electroporation, cells were immediately resuspended in DMEM 
containing 10% (v/v) tbetal bovine serum and plated onto 160 mm 
diameter petri dishes. The cells were allowed to recover for 4 h and then 
the medium was routinely replaced with serum-free DMEM and the 
cells incubated for a further 20 h. For TPA treatment, TPA (phorbol 
12-myristate 13-acetate; Sigma UK) dissolved in ethanol was added to 
the cells to a final concentration f600 ng/ml and incubated for 10 rain 
before harvesting. 
For analysis oftau phosphorylation, cells were harvested by scraping 
into 1.5 ml of chilled phosphate-buffered saline, pelleted by centrifuga- 
tion and then resuspended in 250/tl (a 50 pl aliquot was removed for 
protein analysis using Pierce BCA reagents) pelleted again and resus- 
pended in 60 pl of MES-sodium chloride buffer comprising 100 mM 
MES, pH 6.5, 0.5 mM MgCI2, 1 mM EGTA and 1 M NaCI supple- 
mented with 2 mM DTT, 17.5 pg/ml PMSF, 20pg/ml aprotinin, 50 mM 
sodium fluoride and 0.1 mM sodium vanadate. To isolate tau, the 
harvested cells were heated in a boiling water bath for 5 rain and the 
insoluble fraction removed by centrifugation i a microcentrifuge for 
15 min. The supernatant containing tau was prepared for SDS-PAGE 
by addition of SDS-PAGE sample buffer and analysed by Western 
blotting. 
Analysis of tau phosphorylation byWestern blotting was performed 
as previously described [13]. TP70 is a polyclonal antibody raised in 
rabbits to a tau synthetic peptide corresponding to the C-terminus of 
tau [30]. Monoclonal antibody (mAb) Tau. 1 was obtained from Dr. L. 
Binder, SMI mAbs from Sternberger Monoclonals (Affiniti Research 
Products Ltd., UK) and mAb AT8 from Innogenetics, Ghent, Belgium. 
Monoclonal antibodies 121.5, BF10, RT97 and 8D8 have been de- 
scribed previously [31]. 
2.2. MAP kinase assays 
MAP kinase was extracted and batch-purified by binding to phenyl- 
Sepharose (Pharmacia) and assayed by using bovine myelin basic pro- 
tein (Sigma) as substrate, as previously described [13]. 
3. Results 
3.1. Transfected tau is similarly phosphorylated in
v-raf-transformed 3T3 cells" as in untransformed cells' 
Swiss 3T3 cells were transfected with the cDNA encoding the 
human brain tau isoform with four repeat domains and one 
N-terminal insert, since this is an abundantly expressed isoform 
in brain [32]. Using the TP70 polyclonal antibody to tau that 
recognises normal tau as well as PHF-tau, Western blot analy- 
sis of the heat-stable fraction from these cells revealed two 
bands, the faster-migrating band co-migrated with the recombi- 
nant protein of this isoform (Fig. IA, lanes 1 and 2). The slower 
migration of the upper band is probably due to phosphoryla- 
tion since phosphorylation of tau results in changes in electro- 
phoretic mobility, both in vitro with a number of kinases 
[11,33-36] and in transfected cells [3,13,37-39]. Nevertheless, 
neither tau band was hyperphosphorylated similar to PHF-tau 
nor to the hyperphosphorylated components of adult and foetal 
tau since they were not recognised by monoclonal antibodies 
AT8 or 8D8; these mAbs recognise phosphorylated serines-202 
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Fig. 1. Western blots with (A and E) polyclonal antibody, TP70, that 
recognises both normal tau and hyperphosphorylated PHF-tau; (B and 
F) mAb AT8 that recognises a tau epitope requiring phosphorylation 
of Ser202; (C and G) mAb 8D8 that recognises a tau epitope requiring 
phosphorylation f Ser396; (D and H) mAb Tau 1 that recognises a tau 
epitope requiring non-phosphorylation of Ser~99 and Ser202. For A-D: 
Lanes 1 = recombinant human brain tau; lanes 2 = heat-stable fraction 
from 3T3 cells transfected with tau; lanes 3 = heat-stable fraction from 
v-raf-transformed 3T3 cells transfected with tau; lanes 4 = PHF-tau. 
and -396, respectively, in PHF-tau but do not recognise the 
non-hyperphosphorylated fractions of adult or foetal brain tau, 
nor do they recognise recombinant tau (Fig. 1B and C, lanes 
1, 2 and 4). The mAbs RT97, 1215, SMI31 and SMI34 which 
all recognise phosphorylated sites in PHF-tau [13], also all 
failed to label the tau from the transfected 3T3 cells (data not 
shown). Both tau bands from the transfected cells were labelled 
by mAb Tau 1 which recognises unphosphorylated serine-202 
(Fig. 1D, lane 2). Tau 1, which is specific for the non-hyper- 
phosphorylated fractions of adult and foetal brain tau, also 
labelled non-phosphorylated recombinant tau (Fig. 1 D, lane 1) 
but not PHF-tau (Fig. 1D, lane 4) and so again these results 
demonstrated a lack of hyperphosphorylation f the trans- 
fected tau. If the tau expressed in the 3T3 cells were hyper- 
44 
phosphorylated, wewould predict from our in vitro phospho- 
rylation studies that this isoform would co-migrate with the 
uppermost band of the three prominent PHF-tau bands, and 
transfected tau from the 3T3 cells clearly does not migrate in 
this position (Fig. 1A, lanes 2 and 4) [36]. 
The Western blot pattern of tau in heat-stable fractions from 
transfected v-raf-transformed 3T3 cells was identical to tau 
from transfected control 3T3 cells (Fig. IA, lanes 2 and 3); no 
differences in electrophoretic mobility was observed, and nei- 
ther of the two tau bands was labelled by mAbs AT8 or 8D8 
(Fig. 1B and C, lanes 3), but both bands reacted with mAb Tau 
1 (Fig. 1D, lane 3). The level of MAP kinase activity, measured 
using myelin basic protein as substrate, in extracts from trans- 
formed cells was at least 3-fold higher than that in extracts from 
non-transformed 3T3 cells which is comparable to that previ- 
ously reported for these cell lines [28]. Thus, although transfor- 
mation of 3T3 cells by v-raf resulted in constitutive elevation 
of MAP kinase activity, transfected tau was still not hyper- 
phosphorylated under these conditions. 
3.2. GSK-3fl induced hyperphosphorylation of  tau in 3T3 cells 
When the 3T3 cells were co-transfected with tau and GSK- 
3,8, hyperphosphorylation of tau was observed, although not 
all of the tau was hyperphosphorylated since two bands were 
labelled by the polyclonal antibody, TP70, and only the slower- 
migrating of which co-migrated with the expected component 
in PHF-tau (Fig. 2A, lanes 1 and 2). This slower-migrating 
band was also labelled by mAbs AT8 (Fig. 2B) and 8D8 (Fig. 
2C) but not by Tau 1 (Fig. 2D), whereas Tau 1 but not AT8 
or 8D8 labelled the faster-migrating band of the pair (Fig. 2D). 
Thus, as we previously demonstrated in transfected COS-7 cells 
[13], GSK-3fl leads to hyperphosphorylation of at least a pro- 
portion of tau in 3T3 cells and this was further substantiated 
by the reactivity of the upper band with mAbs RT97, 1215, 
SMI31 and SMI34 (data not shown). 
3.3. Co-tran~fection f tau and p44 M~eK into control and 
v-raf-transformed 3T3 cells" results in elevated tau 
phosphorylation but not hyperphosphorylation 
The GSK-3fl stimulated hyperphosphorylation of tau clearly 
demonstrated that 3T3 cells have the capacity to support he 
formation of hyperphosphorylated tau and so a further attempt 
to elevate the activity of MAP kinase in the cells was made by 
transfection ofa MAP kinase cDNA and treatment of the cells 
with TPA. A p44 MApK cDNA was transiently co-transfected 
with tau into control and v-raf-transformed 3T3 ceils and the 
cells treated with TPA; for comparison, control 3T3 cells tran- 
siently transfected only with tau cDNA were also treated with 
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Fig. 2. Western blots with: (A) polyclonal antibody, TP70; (B) mAb 
AT8; (C) mAb 8D8; (D) mAb Tau 1. For AD:  Lanes 1 = heat-stable 
fraction from 3T3 cells co-transfected with tau and GSK-3fl; lanes 
2 = PHF-tau. 
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Fig. 3. Western blot with polyclonal tau antibody, TP70. Lanes 1 
4 = heat-stable fraction from 3T3 cells (and all treated with TPA); lane 
1 = transfected with tau; lane 2 = 3T3 cells co-transfected with p44 MAPK 
and tau; lane 3 = v-raf-transformed 3T3 cells transfected with tau; lane 
4 = v-raf-transformed 3T3 cells co-transfected with p44 MAPK and tau; 
lane 5 = PHF-tau. 
TPA. The tau in heat-stable fractions from all of these cells was 
analysed by Western blotting. The tau from both control and 
v-raf-transformed 3T3 cells co-transfected with tau and 
p44 MApK cDNAs migrated mainly as a single band (Fig. 3, lanes 
2 and 4, respectively) with the same mobility as the slower- 
migrating band of the tau doublet from either control or v-raf- 
transformed cells transfected only with tau cDNA (Fig. 3, lanes 
1 and 3, respectively). Although this implies that elevation of 
MAP kinase activity through transfection with p44 MAPK cDNA 
and TPA treatment resulted in an increased level of tau phos- 
phorylation, none of the bands migrated in the same position 
as the slowest of the three main PHF-tau bands, as would be 
expected if the tau was hyperphosphorylated similarly to PHF- 
tau (Fig. 3, lanes 2, 4 and 5) [36]. Similarly, none of the tau from 
these cells was labelled by mAbs specific for PHF-tau and 
hyperphosphorylated adult and foetal tau, ie, mAbs ATS, 8D8, 
RT97 1215, SMI31 and SMI34 (data not shown). 
4. Discussion 
The results of this study extend our previous findings that 
GSK-3ct and GSK-3fl hyperphosphorylate tau in co-trans- 
fected COS-7 cells but that neither p44 MAPK nor p42 MAPK led 
to a similar increase in tau phosphorylation in COS cells [13]. 
It is possible that the absence of a MAP kinase-induced hyper- 
phosphorylation f tau that we observed previously was be- 
cause the MAP kinase activity was only transiently activated 
with the peak occurring after 10 min treatment with TPA, and 
noticeably declining after 60 min. However, v-raf-transforma- 
tion that leads to constitutive elevation of MAP kinase activity 
also failed to result in tau hyperphosphorylation. This is un- 
likely to be the result of some other difference between COS-7 
and 3T3 cells because transfected GSK-3fl did induce tau hy- 
perphosphorylation n the 3T3 cells. 
There are several possible xplanations why tau is not hyper- 
phosphorylated by activated MAP kinase in these two non- 
D.A. Latimer et al./FEBS Letters 365 (1995) 42-46 45 
neuronal cell types even though MAP kinase does utilise tau 
as a substrate in vitro. It is unlikely that the lack of phosphoryl- 
ation is due to all activated MAP kinase being translocated to 
the nucleus because we demonstrated previously that a signifi- 
cant fraction remains cytoplasmic [13]. Furthermore in this 
study of 3T3 cells, a shift in mobility of tau was observed when 
it was analysed from cells in which MAP kinase was maximally 
elevated but without generation of PHF-tau or hyper- 
phosphorylated adult and foetal tau epitopes, as monitored 
with available monoclonal antibodies, and the lack of a maxi- 
mal decrease in mobility on SDS-PAGE. This implies that 
cytoplasmic MAP kinase is either capable of phosphorylating 
tau, albeit at non-PHF sites, or activates another kinase which 
utilises the cellular tau as substrate. Indeed, several kinases 
distinct from proline directed kinases can induce a shift in 
electrophoretic mobility of tau [33-35,40]. Interestingly, this 
change in tau mobility in p44 MAPK transfected cells was not 
restricted to the v-raf-transformed cells which suggests that 
transfection with MAP kinase and treatment with TPA to stim- 
ulate the MAP kinase transiently, was sufficient o lead to a 
change in tau phosphorylation over and above that in TPA- 
treated control cells transfected only with tau. 
It has been shown in several non-neuronal cells, including 
N1H3T3 cells, that activation of MAP kinase results in a de- 
crease in activity of endogenous GSK-3. This is because MAP 
kinase stimulates MAP kinase-activated protein kinase-lfl 
(MAPKAP), also known as p90 ribosomal protein $6 kinase-2 
(Rsk2), which in turn phosphorylates and inactivates GSK-3 
[41 44] .  There are therefore interesting implications for treating 
Alzheimer's disease since nerve growth factor, which is consid- 
ered as a potential therapeutic agent [45,46], activates MAP 
kinase in neuronal cells and so this neurotrophin might lead to 
a reduction in the amount of hyperphosphorylated neuronal 
tau in degenerating neurones. Indeed, we demonstrated previ- 
ously that treatment of primary neurones in culture with TPA 
did activate MAP kinase and produced a modest reduction in 
the proportion of foetal tau that is hyperphosphorylated in 
these cells [13]. Clearly, it is now important o establish une- 
quivocally the identity of the kinases responsible for the phos- 
phorylation of neuronal tau in vivo and the mechanisms regu- 
lating these kinases. 
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